Answers are grounded in this paper and cite their sources.
New technologies, such as nonreplacement and gene therapies, have emerged to mitigate the treatment burden and other limitations associated with factor replacement therapy for hemophilia B. Gene therapies, in particular, show promise as potential cures; however, they pose unique challenges to managed care pharmacy and warrant guidance for payers. AMCP Market Insights virtually convened an expert panel of managed care stakeholders in June 2026 to gather this guidance through examining the current and future state of hemophilia B gene therapy. This article provides a qualitative summary of the panel discussion along with key insights and suggested payer practices meant to support informed coverage decisions and guide future work such as collaboration, research, and advocacy. Key insights underscore that the current treatment paradigm requiring factor replacement therapy for hemophilia B is suboptimal as it is associated with adherence limitations and cost unpredictability; to improve its value, participants suggest payers direct patients with hemophilia to receive care in hemophilia treatment centers, provide high-touch, hemophilia-specific care management, and designate specialized reviewers for hemophilia-related coverage requests. Additional findings are that hemophilia B gene therapy has clinical value, but effective delivery requires multiple solutions involving collaboration among stakeholders to overcome both organizational and systemic challenges such as low usage and inadequate funding methods. Essential to effective delivery is evidence generation to better understand patient and provider decision-making, to determine safety and effectiveness in subpopulations, to assess long-term durability, and to evaluate cost outcomes. Also essential is improving the ability to implement alternative financing methods, which participants suggest could be done with enhanced outcomes tracking infrastructure and deeper analysis of internal payer data to assess cost-effectiveness and determine value.
No takes yet. Share an insight, caveat, or question.
Flavin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: